REFRACTORY PLASMABLASTIC LYMPHOMA

Clinical trials for REFRACTORY PLASMABLASTIC LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new REFRACTORY PLASMABLASTIC LYMPHOMA trials appear

Sign up with your email to follow new studies for REFRACTORY PLASMABLASTIC LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Not yet recruiting 1 Terminated 1

New immune therapy tested for aggressive lymphoma that Won't quit

Disease control Not yet recruiting

This early-stage study is testing a new drug called teclistamab in adults whose plasmablastic lymphoma has come back or hasn't responded to previous treatments. The main goals are to find the safest dose and see what side effects occur, while also checking if the drug helps contr…

Matched conditions: REFRACTORY PLASMABLASTIC LYMPHOMA

Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 19, 2026 14:56 UTC

REFRACTORY PLASMABLASTIC LYMPHOMA

Get alerted when new REFRACTORY PLASMABLASTIC LYMPHOMA trials appear

New immune therapy tested for aggressive lymphoma that Won't quit